Resumo

MALDONADO, Génessis; FERRO, Christian; PAREDES, Carlos  e  RIOS, Carlos. Use of denosumab in osteogenesis imperfecta: A case report. Rev.Colomb.Reumatol. [online]. 2019, vol.26, n.1, pp.68-73. ISSN 0121-8123.

Osteogenesis imperfecta (01) is an inherited disorder of phenotypically heterogeneous affec tions of the connective tissue. Until now, no definitive treatment for OI has been found. Certain drugs used in osteoporosis are used in these patients such as intravenous bisphosphonates in order to improve bone density. However, in recent years the use of denosumab, an anti-resorptive monoclonal antibody has shown positive results in bone mineral loss. There are no studies that directly compare the use of bisphosphonates and denosumab in OI. The following article presents a case of a 9-year-old patient with diagnosis of OI and a past medical history of epilepsy and cerebral palsy that was treated with bisphosphonates and denosumab.

Palavras-chave : Osteogenesis imperfecta; Heterogeneity; Fractures; Denosumab.

        · resumo em Espanhol     · texto em Inglês     · Inglês ( pdf )